TY - JOUR
T1 - Organic NIR-II dyes with ultralong circulation persistence for image-guided delivery and therapy
AU - Li, Yang
AU - Gao, Jianfeng
AU - Wang, Shuping
AU - Li, Shijun
AU - Hou, Xiaowen
AU - Pan, Yanna
AU - Gao, Jialu
AU - Qiao, Xue
AU - Tian, Zhiquan
AU - Chen, Deliang
AU - Deng, Hai
AU - Deng, Zixin
AU - Hong, Xuechuan
AU - Xiao, Yuling
N1 - Acknowledgments
This work was partially supported by grants from the National Key R&D Program of China (2020YFA0908800), NSFC (82111530209, 81773674, 91959103, 81573383, 21763002), Shenzhen Science and Technology Research Grant (JCYJ20190808152019182), the Applied Basic Research Program of Wuhan Municipal Bureau of Science and Technology (2019020701011429), Hubei Province Scientific and Technical Innovation Key Project (2020BAB058), the Local Development Funds of Science and Technology Department of Tibet (XZ202102YD0033C, XZ202001YD0028C), and the Fundamental Research Funds for the Central Universities.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers selfassembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1-4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.
AB - Nanocarriers hold great promise for the controlled release of therapeutic payloads to target organs/tissues and extended duration of anticancer agents in the bloodstream. However, limited data on their in vivo pharmacokinetics and delivery process hamper clinical applications. Here we report a series of micellar nanocarriers selfassembled from new-generation thiophenthiadiazole (TTD)-based NIR-II fluorophores HLAnP (n = 1-4) for simultaneous bioimaging and drug delivery. The NIR-II HLA4P nanocarrier displays exceptional non-fouling performance, minimal immunogenicity, ultralong blood half-life, and high tumor accumulation even with different administration routes. When used as a drug carrier, HLA4P with encapsulated doxorubicin (DOX) realized accurate tumor targeting and continuous real-time in vivo NIR-II tracking of drug delivery and therapy, showing a sustained release rate, improved therapeutic effect, and diminished cardiotoxicity as compared to free DOX. This study provides a new perspective on the design of dual-functional NIR-II fluorophores for diagnostic and therapeutic applications.
KW - China
KW - Drug delivery
KW - Image-guided therapy
KW - Second near-infrared window (NIR-II)
KW - Self-assembly
KW - Fluorescence imaging
U2 - 10.1016/j.jconrel.2022.01.005
DO - 10.1016/j.jconrel.2022.01.005
M3 - Article
VL - 342
SP - 157
EP - 169
JO - Journal of Controlled Release
JF - Journal of Controlled Release
SN - 0168-3659
ER -